<SEC-DOCUMENT>0001493152-26-035498.txt : 20260730
<SEC-HEADER>0001493152-26-035498.hdr.sgml : 20260730
<ACCEPTANCE-DATETIME>20260730172319
ACCESSION NUMBER:		0001493152-26-035498
CONFORMED SUBMISSION TYPE:	425
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260730
DATE AS OF CHANGE:		20260730

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		425
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41615
		FILM NUMBER:		261224550

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		425

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
</SEC-HEADER>
<DOCUMENT>
<TYPE>425
<SEQUENCE>1
<FILENAME>form425.htm
<DESCRIPTION>425
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by Mangoceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 425 under the Securities Act of 1933, as amended,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
deemed filed pursuant to Rule 14a-12</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934, as amended</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
Company: Nuclea Energy Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File No.: 001-41615</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2026, the following press release was issued by Nuclea Energy Inc., in connection with the proposed business combination contemplated
by the Business Combination Agreement described in the Current Report on Form 8-K filed by Mangoceuticals, Inc. with the Securities and
Exchange Commission on July 30, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="form425_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nuclea
Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance
the Morpheus Microreactor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transaction
positions Nuclea to fund the development and commercialization of its lead-cooled, factory-built microreactor as AI and data center growth
drives a generational expansion in U.S. electricity demand</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISSISSAUGA,
Ontario &ndash; July 30, 2026</B> &ndash; Nuclea Energy Inc. (&ldquo;Nuclea&rdquo; or the &ldquo;Company&rdquo;), an advanced nuclear
technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular
reactor, today announced that it has entered into a definitive business combination agreement (the &ldquo;Business Combination Agreement&rdquo;)
with Mangoceuticals, Inc. (NASDAQ: MGRX) (&ldquo;Mangoceuticals&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
agreement gives Nuclea a faster path to the public markets at a defining moment for our industry. Demand for continuous, carbon-free
power is accelerating, and microreactors are built to serve the data centers, defense installations and remote sites that the grid cannot
efficiently reach. As a public company, we expect to have the capital access and visibility to advance Morpheus toward first-of-a-kind
delivery and to execute on our commercialization roadmap,&rdquo; said Josef Freundorfer, Chief Executive Officer of Nuclea Energy Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Business Combination Agreement, a newly formed indirect subsidiary of Mangoceuticals will amalgamate with Nuclea under the Business
Corporations Act (British Columbia), with the resulting amalgamated company becoming an indirect wholly owned subsidiary of Mangoceuticals.
In connection with the amalgamation, holders of Nuclea common shares will receive exchangeable shares of a newly formed British Columbia
unlimited liability company and wholly owned subsidiary of Mangoceuticals (&ldquo;ExchangeCo&rdquo;), in accordance with the exchange
ratio set out in the Business Combination Agreement. The Exchangeable Shares will be exchangeable for shares of Mangoceuticals common
stock and will carry economic and voting rights intended to be substantially equivalent to those of Mangoceuticals common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Business Combination Agreement, each Nuclea common share outstanding immediately prior to closing will be converted
into the right to receive exchangeable shares determined in accordance with an exchange ratio such that, immediately following closing
and assuming the exchange of all exchangeable shares for Mangoceuticals common stock, former Nuclea shareholders would hold approximately
96% of the outstanding equity of Mangoceuticals on a fully diluted and as-exchanged basis immediately following Completion and prior
to giving effect to the PIPE Share Issuance, and Mangoceuticals&rsquo; existing stockholders would hold approximately 4%, in each case
calculated on a fully diluted and as-exchanged basis and subject to certain adjustments set forth in the Business Combination Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Importantly,
the closing of the transaction is expected to occur prior to receipt of the Required Approvals (as defined below). Until such time as
both (i) Mangoceuticals stockholder approval and (ii) Nasdaq approval of the initial listing application (collectively, the &ldquo;Required
Approvals&rdquo;) have been obtained, the aggregate economic rights, all voting rights and exchange rights attributable to the Exchangeable
Shares, together with any Mangoceuticals common stock issued in connection with the transaction, will be limited by a cap equal to 19.99%
of the outstanding Mangoceuticals common stock immediately prior to closing (the &ldquo;Nasdaq Cap&rdquo;). No Exchangeable Shareholder
will be entitled to receive, exercise or realize any economic, voting or exchange rights in excess of the Nasdaq Cap until the Required
Approvals have been obtained. Any such rights in excess of the Nasdaq Cap will be deferred, and not extinguished, pending receipt of
the Required Approvals. Following receipt of the Required Approvals, the Exchangeable Shares will provide holders with the full economic,
voting and exchange rights contemplated by the Agreement, and Mangoceuticals will take all actions necessary to permit the issuance and
realization of all rights previously restricted by the Nasdaq Cap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction is intended to provide Nuclea with a public listing on Nasdaq, broadening its access to the capital markets to fund the continued
development, licensing and commercialization of Morpheus at a time when demand for reliable, carbon-free electricity is accelerating.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
two decades of largely flat consumption, U.S. electricity demand is projected to rise sharply, driven substantially by the build-out
of artificial intelligence infrastructure and hyperscale data centers, alongside broader electrification and the reshoring of domestic
manufacturing. Nuclea believes nuclear power is one of the few proven, scalable technologies capable of delivering the continuous, carbon-free
baseload electricity this demand requires, and that advanced microreactors are particularly well suited to serve data centers, defense
installations and remote or off-grid sites that cannot be efficiently served by the grid or by intermittent renewable generation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nuclea
also believes it is positioned to benefit from tailwinds specific to advanced nuclear, including growing hyperscaler and government interest
in on-site and co-located power, the potential for factory-built, transportable reactors to shorten construction timelines and reduce
capital costs relative to conventional nuclear plants, and increasing policy support for domestic advanced reactor licensing and deployment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Morpheus Microreactor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morpheus
is a lead-cooled, graphite-moderated microreactor currently in the conceptual design stage, scalable from approximately 3.5 MWe to 50
MWe of output. The design incorporates inherent safety characteristics associated with lead coolant, including a high boiling point that
provides substantial thermal margin, near-atmospheric operating pressure, passive natural-convection cooling that requires no pumps,
and the absence of water or steam within the reactor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nuclea
has also developed a proprietary, patent-pending annular fuel configuration designed to extend the reactor&rsquo;s refueling cycle to
up to five years, well beyond the industry standard of approximately 1.5 years. Morpheus is designed to be factory-fabricated and transportable
via standard rail and road shipping methods, with identified use cases across data centers, defense and military installations, remote
mining operations and remote communities currently reliant on diesel generation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transaction
Details</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the number of shares issuable in connection with the transaction would exceed 19.99% of Mangoceuticals&rsquo; outstanding common stock,
completion of the transaction requires the approval of Mangoceuticals&rsquo; stockholders under applicable Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the transaction, Mangoceuticals has agreed to appoint at least three individuals designated by Nuclea to its Board of
Directors at or promptly following closing, subject to applicable Nasdaq requirements and director qualification standards. Mangoceuticals
has also agreed to obtain voting support agreements from certain of its stockholders in support of the stockholder approval described
above, and certain principal shareholders of Nuclea and of Mangoceuticals have agreed to customary lock-up arrangements with respect
to the securities they receive pursuant tothe transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction has been approved by the Boards of Directors of both Nuclea and Mangoceuticals. Completion of the transaction is subject
to customary closing conditions, including the approval of the amalgamation by Nuclea&rsquo;s shareholders, the approval of Mangoceuticals&rsquo;
stockholders described above, receipt of applicable regulatory approvals, including under the Investment Canada Act, the Competition
Act (Canada) and the Hart-Scott-Rodino Antitrust Improvements Act, as applicable, and Nasdaq&rsquo;s non-objection to the transaction
and the exchangeable share structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Joseph
Gunnar &amp; Co., LLC is serving as the exclusive financial advisor for the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
scale of capital being committed to power the AI build-out is enormous, and we believe advanced nuclear and microreactors will be a critical
part of how that demand is met. Nuclea brings a differentiated, inherently safe reactor design, a strong technical and regulatory team,
and a clear roadmap to commercialization, and we are excited to bring this opportunity to our shareholders,&rdquo; said Jacob Cohen,
Chief Executive Officer of Mangoceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Nuclea Energy Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nuclea
Energy Inc. is an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a
lead-cooled, graphite-moderated micro-modular reactor designed to be factory-built, transportable and scalable from approximately 3.5
MWe to 50 MWe. Nuclea is targeting applications across data centers, defense installations, remote industrial operations and off-grid
communities. For more information, visit <U>www.NucleaEnergy.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Mangoceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MangoRx
is focused on developing a variety of men&rsquo;s health and wellness products and services via a secure telemedicine platform. To date,
the Company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth,
hormone replacement therapies, and weight management. Interested consumers can use MangoRx&rsquo;s telemedicine platform for a smooth
experience. Prescription requests will be reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped
through MangoRx&rsquo;s partner compounding pharmacy and right to the patient&rsquo;s doorstep. To learn more about MangoRx&rsquo;s mission
and other products, please visit <U>www.MangoRx.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the proposed transaction, Mangoceuticals intends to file relevant materials with the U.S. Securities and Exchange Commission
(the &ldquo;SEC&rdquo;), including a proxy statement in connection with the stockholder approval described above. INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN
THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will
be able to obtain free copies of these documents through the website maintained by the SEC at www.sec.gov, or by directing a request
to Mangoceuticals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants
in the Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Nuclea and their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed
to be participants in the solicitation of proxies from Mangoceuticals&rsquo; stockholders in connection with the transaction. Investors
and security holders may obtain more detailed information regarding the names, affiliations and interests of Mangoceuticals&rsquo; executive
officers and directors in its most recent Annual Report on Form 10-K and other filings with the SEC. Additional information regarding
the persons who may be deemed participants in the solicitation and their interests will be set forth in the proxy statement and other
relevant materials when they become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Offer or Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any
securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the
proposed transaction and its expected structure, timing and completion; the anticipated ownership percentages of Mangoceuticals following
closing; the anticipated benefits of a public listing; projected electricity demand; and the development, licensing, commercialization
and performance of the Morpheus microreactor, which remains in the conceptual design stage. Forward-looking statements are based on current
expectations and assumptions and are subject to significant risks and uncertainties, including the risk that the transaction may not
be completed on the anticipated terms or timing, or at all; the ability to obtain required regulatory, Nasdaq and stockholder approvals;
the ability to obtain nuclear licensing approvals; the availability of capital; and technology development risks. Actual results may
differ materially from those expressed or implied. Neither Nuclea nor Mangoceuticals undertakes any obligation to update forward-looking
statements except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nuclea
Energy Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORE
IR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ir@nuclea.energy</U><BR>
(437) 784-1600</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 371.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mangoceuticals,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investors@mangorx.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form425_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form425_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F 48# 2(  A$! Q$!_\0
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M+6]3$SERN^JU-L5.25-O>U_OV_ Y/P)KDNH:8^FWV5U&P/E2ANK*. ?KV/\
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MM_\ T8M>\_'C_DGT7_7_ !_^@O7@W@S_ )'G0/\ L(V__HQ:]Y^/'_)/HO\
MK_C_ /07I#.?_9W_ -1XB_WK?^4E>W5XC^SO_J/$7^];_P I*]NIB.:^(7_)
M/-?_ .O*3^5>&_ G_DH;?]>4O\UKW+XA?\D\U_\ Z\I/Y5X;\"?^2AM_UY2_
MS6@#O_C#\19O#T T'29#'J-Q'OFG4\PQGC ]&/KV'U!'GOP[^%4_C6W;5=0N
MY+731(54JN9)R.NTG@#/&>><\5S'CC49-9\>:S=,2Q>[>./_ '5.Q1^0%?6.
MA:7%HF@V.F0* EK L7'<@<G\3D_C2&<1_P */\&>1Y?DWN_&/-^TG=_+'Z5Y
M3\1/A;<>"8DU.QNWNM-:0)N88DA;MNQP1QU&.>U?3M9VNZ)9^(M%N=)U!6:U
MN  X0X/!!!!^H%,1Q/PA\<S>*]#ELM0<OJ6GA5>0GF9#G:Q]^,'\#WKY\T;_
M )'73_\ L(Q_^C!7TYX5^'&A>#M1EOM*-V)98C$XEEW*5R#TQUR!7S'HW_(Z
MZ?\ ]A&/_P!&"D,^G?B'XUB\$^'#=JBRWL[&*UB/0MC[Q_V1W_ =Z^?_  IX
M4UKXG^(KJXN+U@JD27=[,-V,]% [G@X'  %=1^T#>M)XITNQSE(+,RX]"[D'
M]$%:?PQ\?^#_  EX-BLKV\DCOY97FN MN[<DX7D#GY0M '6V7P1\&6UL(Y[6
MYNY,<RRW#*2?HI _2N'\??!6/2=,N-7\/7$LD-NADFM)OF8*.I1AUP.<'TZ]
MJ[W_ (73X(_Z"4__ ("R?X4U_C-X&D1D?4)F5A@@VLF"/RIB.*^"OC^<7<?A
M34Y6DC<'[#*YR4(&3&?; X].G<8T?CIXRN=/AM_#5C(T1NHO.NI%."8R2 GT
M)!S]!ZFO%;6_CTCQ/%?V#DQ6MX)86P02JOD?F!7U#XC^''ASQ=J2ZGJ<=P\_
ME+&#',5&T9(X_$TAGE'PU^$-MXDTB+7-;N)5M)B?(MH3M9P#C<S=AD'@?7->
MB3_!7P3-;M''87$#D8$L=TY8>_S$C]*UQXA\(>"=,@TF36;2WBM$\M83-YD@
M ]5&3^E8&H?'+PA:*WV9KV]8=!% 5!_%\4Q'BWC+PS>_#CQ?#%;7S,55;FTN
M4&U@,D#/N"#]?QQ7TWX4UK_A(O"NFZL5"O<P!G4= _1L>V0:^7/'GC.?QQKX
MU&2W6VABC$,,(;<54$GD]R237T/\)O\ DE^B?[DG_HUZ0SM****8@K@?'6JO
M>7EOX?M'&YW4S$G R3\JG^9_"NRU6^&FZ5<WI7=Y,98+ZGM^M>0:=977B#5W
M!F032DR222M@#GD_KTKFKSLN5;L]S*,/&4GB)Z*/Y_\  .ZF\0:;X7TV+3-/
M NKB-<';]W=W+'USV'Z5GIX7UGQ$6O=5N_(+#,:,N2/^ Y^4?K6MI=AX<\/@
M227UM-=#K([@D?[JCI_.K<WC318L[9WE/_3.,_UQ4)K_ )>22\KEN<X-_5(-
MM[R:U?IV1YNEUJ>@7L\$$\EO*K;)%4\$CV[UT:3_ ! 6)9$1W5AD!DBS^76L
MWQ)J$.K:DNH65K-&%4!W=>I!X/&?:O1="U:/6=+CNEP)/NRJ/X6'7_'\:VH3
M5[+4O'3DJ<:DJ:N][]&<0VO^/K;[VD^;C_IV)_\ 035>7Q[XO@1A-X="MC[Q
MMI0!^M>HT5Z,,137Q4T_O/#E4B_LH^;='U^[T+7H]4B&Z56/F(> X/W@:[27
MQ!XK^(,IL]&MCI^G_=ED#G'_  )\?H!^=9U_IEIKGQ?EL$B'V9[K]ZJ\9VKE
M_P R&_.O9@MGI.GG:L5M:6Z%B% 544#)X%>QC,33AR34+S:5K]/EU?8REJ>-
M^,?"^E>$O#]O9(#>ZQ>R#]\W!15Z[5'3)('.<\UZ1X'\-KX9\.Q6[J/M<W[V
MX;_:/\/T X_/UKB_"BOXY\?W?B&[1OL5C@6R-T!S\@_#EC[D5ZS7)CZ]2,%0
MF[O>7J]E\C&"N^8*\ _:$_Y#NC?]>S_^A5[_ %X!^T)_R'=&_P"O9_\ T*O'
M-3KO@+_R(%Q_V$)/_0(Z]1KR[X"_\B!<?]A"3_T".O4: /"_CAX&V/\ \)7I
M\7RMA+Y%'0]%D_D#^'O5#X->-S:"X\+7\O[B='>R9C]R3!)3Z'J/?/K7OMW:
MP7UI-:742RP3(8Y(V'#*1@@U\F^-O"]WX#\7-;QLXA#">RG[E,Y'/]X'@_3W
MI#*'@S_D>= _["-O_P"C%KWGX\?\D^B_Z_X__07KP;P9_P CSH'_ &$;?_T8
MM?0GQKL);WX<7+Q*6^RSQSL!_=R5/Y;L_A0!RG[._P#J/$7^];_RDKVZOG?X
M$^);'2=:U#2[Z9(3J"QF%W.%+IN^7/J0W'T]Z^B*8CFOB$<?#S7\_P#/E)_*
MO#?@3_R4-O\ KRE_FM=U\:O'%E::#-X:LKA);^Z(%P$.?)C!R0?1C@#'IGVK
MA?@3_P E#;_KRE_FM(#B]?B?3O&&IQR*=T%_*"#WPYK['@F2X@CFB8-'(H=2
M.X(R*^=/CAX5ETOQ.-=AC/V+40-[ <),!@@_4 'W^;TKO/@[X\M=7T"#0;ZX
MCCU*R411*[8,\0^[CU('!'L#0,]3J*ZNK>RMI+FZGC@@C&YY9&"JH]23TJ6O
M)/C7XULK3P_+X;M)TEO[LJ)U0Y\F,$$[O0D@#'IGVIB/2-/\1Z)J]P;?3=8L
M+R8*7,=O<([!>!G /3D?G7R1HW_(ZZ?_ -A&/_T8*]8_9^T*56U37I$*QLHM
M(21][D,_\D_6O)]&_P"1UT__ +",?_HP4AG=_'R!H_'5I*?NR:>F#[AW!_I6
MEX(^$&A^*_"-CK$FIWT<LX821Q[,*RL5QR/;]:Z'X[^&)M2T.TURU0N^GEEG
M4#GRFQ\WX$?^/$]JY/X,_$"UT"6;0=7G$-E<R>9!.YPL4AX(8]@<#GH"/>@#
MJ_\ AGW0/^@OJ7_D/_XFC_AGW0/^@OJ7_D/_ .)KUQ'61%=&#*PR&!R"*YSQ
MGXRT[P=HLMW=3(;HH?LUMGYI7[<>F>I[4Q'#?\,^Z!_T%]2_\A__ !-<K\6_
M'NHKK$GA?2[R2"PLD6*=XFVM,^T9!([#ICUSG/%8?P]D\0^*_'EE ^JZ@\"2
M_:;H_:'VA%.2",]"<+^-87CV&6W^(.OI.#O-_*_/=68LOZ$4AG5>$?@OK/B.
MQAU&^NH]-LYE#Q[D+RNIZ';D  ^Y_"O1-+^ _A>S=7O9[Z_8=4>01H?P49_6
MO1-&U&SU71K2^T^1)+66)6C*'@#'3V(Z8[8J:^O[33+*6]OKB.WMH5W222'
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M3],X/L<UWM8OB?1?[:TEHT'^D1?/$?4^GX_X4YQZK=%4*O+>$OAEO_F;5(2
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MH6VRWA9'\Z7:<EL\<5ZM14C.)^%OA;4O"'A673M4\GSVNWF'E/N&TJH'./\
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M?I6E3(HHX(Q'#&D<:]%1< ?@*?0!BRQ1WVOW%M>,QCB@C>&+>5!R6W-P>2,
M>WXU>TV2%M/A,-P\\7*I+(<LV"1U[].O<<\]:DNK&TOE5;NUAG"G*B6,-CZ9
MJ0P0D1@Q)B(YC&T?(<8X]."10!)1110 4444 %%%% !1110 5'+;PS[?.ACD
MVG*[U!P?;-%% $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
